clinical trial · NCT06541665
Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL
Ono Pharmaceutical Co., Ltd.·phase1·active not recruiting·n = 20
Primary Central Nervous System LymphomaONO-4059RituximabMethotrexateProcarbazineVincristine
brief summary
To confirm the tolerability and safety of combined administration of ONO-4059 and R-MPV therapy in untreated PCNSL patients.
started
May 17, 2024
primary completion
Apr 28, 2028
completion
Aug 31, 2028
last updated
Jun 3, 2025
official title
A Multicenter, Phase I, Open-label, Uncontrolled Study of ONO-4059 in Combination With Rituximab, Methotrexate, Procarbazine, and Vincristine (R-MPV) Therapy for Untreated Primary Central Nervous System Lymphoma (PCNSL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol